These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24643574)

  • 21. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
    Grills IS; Mangona VS; Welsh R; Chmielewski G; McInerney E; Martin S; Wloch J; Ye H; Kestin LL
    J Clin Oncol; 2010 Feb; 28(6):928-35. PubMed ID: 20065181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
    Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
    Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Outcome of three-dimensional conformal radiotherapy for early stage non-small cell lung cancer patients who met or not inclusion criteria for stereotactic-body radiation therapy].
    Kołodziejczyk M; Kępka L; Tyc-Szczepaniak D; Wierzchowski M
    Pneumonol Alergol Pol; 2011; 79(5):326-36. PubMed ID: 21861256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of carbon-ion radiotherapy versus stereotactic body radiotherapy for non-small-cell lung cancer.
    Okazaki S; Shibuya K; Takura T; Miyasaka Y; Kawamura H; Ohno T
    Cancer Sci; 2022 Feb; 113(2):674-683. PubMed ID: 34820994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of stereotactic body radiotherapy versus conventional fractionated radiotherapy for medically inoperable, early-stage non-small cell lung cancer.
    Sun H; Wang H; Wei Y; Wang H; Jin C; Chen Y
    Cost Eff Resour Alloc; 2023 Jul; 21(1):46. PubMed ID: 37507748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
    Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
    Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha/beta ratio for normal lung tissue as estimated from lung cancer patients treated with stereotactic body and conventionally fractionated radiation therapy.
    Scheenstra AE; Rossi MM; Belderbos JS; Damen EM; Lebesque JV; Sonke JJ
    Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):224-8. PubMed ID: 24331668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
    Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer.
    Yu JB; Soulos PR; Cramer LD; Decker RH; Kim AW; Gross CP
    Cancer; 2015 Jul; 121(14):2341-9. PubMed ID: 25847699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer.
    Robinson CG; DeWees TA; El Naqa IM; Creach KM; Olsen JR; Crabtree TD; Meyers BF; Puri V; Bell JM; Parikh PJ; Bradley JD
    J Thorac Oncol; 2013 Feb; 8(2):192-201. PubMed ID: 23287852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults.
    Smith BD; Jiang J; Chang JY; Welsh J; Likhacheva A; Buchholz TA; Swisher SG; Shirvani SM
    J Geriatr Oncol; 2015 Jul; 6(4):324-31. PubMed ID: 26094172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery.
    Palma D; Visser O; Lagerwaard FJ; Belderbos J; Slotman B; Senan S
    Radiother Oncol; 2011 Nov; 101(2):240-4. PubMed ID: 21775007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the outcomes of stereotactic body radiotherapy and surgery in elderly patients with cT1-2N0M0 non-small cell lung cancer.
    Nakagawa T; Negoro Y; Matsuoka T; Okumura N; Dodo Y
    Respir Investig; 2014 Jul; 52(4):221-6. PubMed ID: 24998368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Koshy M; Malik R; Weichselbaum RR; Sher DJ
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):344-50. PubMed ID: 25636759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis.
    Guckenberger M; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N
    J Thorac Oncol; 2013 Aug; 8(8):1050-8. PubMed ID: 23817193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases.
    Hall MD; McGee JL; McGee MC; Hall KA; Neils DM; Klopfenstein JD; Elwood PW
    J Neurosurg; 2014 Dec; 121 Suppl():84-90. PubMed ID: 25434941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unresected stage III non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Okawara G; Rusthoven J; Newman T; Findlay B; Evans W
    Cancer Prev Control; 1997 Aug; 1(3):249-59. PubMed ID: 9765750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: long-term results and efficacy of adjuvant chemotherapy.
    Chen Y; Guo W; Lu Y; Zou B
    Radiother Oncol; 2008 Sep; 88(3):351-8. PubMed ID: 18722684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
    Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palliative efficacy and local control of conventional radiotherapy for lung metastases.
    Fleming C; Rimner A; Foster A; Woo KM; Zhang Z; Wu AJ
    Ann Palliat Med; 2017 Aug; 6(Suppl 1):S21-S27. PubMed ID: 28595431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.